Molecular profile of CD34+stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia

被引：19

作者：

Catani, L. ^{[1
]}

Zini, R. ^{[2
]}

Sollazzo, D. ^{[1
]}

Ottaviani, E. ^{[1
]}

Vannucchi, A. M. ^{[3
]}

Ferrari, S. ^{[2
]}

Baccarani, M. ^{[1
]}

Vianelli, N. ^{[1
]}

Lemoli, R. M. ^{[1
]}

Manfredini, R. ^{[2
]}

机构：

[1] Univ Bologna, Dept Hematol & Oncol Sci L&A Seragnoli, Bologna, Italy

[2] Univ Modena & Reggio Emilia, Sect Biol Chem, Dept Biomed Sci, Modena, Italy

[3] Univ Florence, Dept Hematol, Florence, Italy

来源：

LEUKEMIA | 2009年 / 23卷 / 05期

关键词：

JAK2; V617F; EXPRESSION;

D O I：

10.1038/leu.2008.357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：997 / 1000

页数：5

共 8 条

[1] Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation [J].

Campbell, Peter J. ;

Baxter, E. Joanna ;

Beer, Philip A. ;

Scott, Linda M. ;

Bench, Anthony J. ;

Huntly, Brian J. P. ;

Erber, Wendy N. ;

Kusec, Rajko ;

Larsen, Thomas Stauffer ;

Giraudier, Stephane ;

Le Bousse-Kerdiles, Marie-Caroline ;

Griesshammer, Martin ;

Reilly, John T. ;

Cheung, Betty Y. ;

Harrison, Claire N. ;

Green, Anthony R. .

BLOOD, 2006, 108 (10) :3548-3555

[2]

KOVACS R, 2005, BLOOD, V106, P3374

[3] The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment [J].

Manfredini, R ;

Zini, R ;

Salati, S ;

Siena, M ;

Tenedini, E ;

Tagliafico, E ;

Montanari, M ;

Zanocco-Marani, T ;

Gemelli, C ;

Vignudelli, T ;

Grande, A ;

Fogli, M ;

Rossi, L ;

Fagioli, ME ;

Catani, L ;

Lemoli, RM ;

Ferrari, S .

STEM CELLS, 2005, 23 (04) :496-506

[4] Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens [J].

Moliterno, Alison R. ;

Williams, Donna M. ;

Rogers, Ophelia ;

Isaacs, Mary Ann ;

Spivak, Jerry L. .

EXPERIMENTAL HEMATOLOGY, 2008, 36 (11) :1480-1486

[5] Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders [J].

Passamonti, F ;

Rumi, E ;

Pietra, D ;

Della Porta, MG ;

Boveri, E ;

Pascutto, C ;

Vanelli, L ;

Arcaini, L ;

Burcheri, S ;

Malcovati, L ;

Lazzarino, M ;

Cazzola, M .

BLOOD, 2006, 107 (09) :3676-3682

[6] Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia [J].

Puigdecanet, E. ;

Espinet, B. ;

Lozano, J. J. ;

Sumoy, L. ;

Bellosillo, B. ;

Arenillas, L. ;

Alvarez-Larran, A. ;

Sole, F. ;

Serrano, S. ;

Besses, C. ;

Florensa, L. .

LEUKEMIA, 2008, 22 (07) :1368-1376

[7] JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders [J].

Rumi, Elisa ;

Passamonti, Francesco ;

Pietra, Daniela ;

Della Porta, Matteo G. ;

Arcaini, Luca ;

Boggi, Sabrina ;

Elena, Chiara ;

Boveri, Emanuela ;

Pascutto, Cristiana ;

Lazzarino, Mario ;

Cazzola, Mario .

CANCER, 2006, 107 (09) :2206-2211

[8] JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling [J].

Schwernmers, Sven ;

Will, Britta ;

Waller, Cornelius E. ;

Abdulkarim, Khadija ;

Johansson, Peter ;

Andreasson, Bjorn ;

Pahl, Heike L. .

EXPERIMENTAL HEMATOLOGY, 2007, 35 (11) :1695-1703

← 1 →